These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4770896)

  • 21. [Intravenous verapamil in the treatment of acute coronary insufficiency].
    Albuquerque DC; da Rocha PJ; Albanesi Filho FM; Benchimol CB; Albuquerque EN; Schlesinger P; Benchimol AB
    Arq Bras Cardiol; 1979 Apr; 32(4):269-72. PubMed ID: 508109
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of finoptin on cerebrocardiac correlations in atherosclerotic circulatory encephalopathy in patients with ischemic heart disease].
    Dubenko OE; Ermakovich II
    Vrach Delo; 1988 Mar; (3):39-42. PubMed ID: 3394295
    [No Abstract]   [Full Text] [Related]  

  • 23. [A comparative evaluation of the anti-ischemic action of verapamil in different models of myocardial ischemia].
    Gurbanov KK; Kovalev GV; Paperno AA
    Farmakol Toksikol; 1991; 54(4):21-3. PubMed ID: 1786814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of the collateral coronary circulation in the mechanism of action of verapamil and diltiazem on the ischemic myocardium].
    Kirsanova GIu; Tsorin IB; Chichkanov GG
    Farmakol Toksikol; 1989; 52(3):33-7. PubMed ID: 2792350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of verapamil in the treatment of ventricular extrasystole in chronic Chagas' heart disease].
    Vichi FL; Nobre F; Evora P; Ribeiro PJ; Papa MV
    Arq Bras Cardiol; 1977 Feb; 30 Suppl 1():101-6. PubMed ID: 407891
    [No Abstract]   [Full Text] [Related]  

  • 26. [On the clinical trial of a heart and coronary drug].
    Eisel K; Kaiser H
    Ther Ggw; 1968 Feb; 107(2):231-2 passim. PubMed ID: 5718464
    [No Abstract]   [Full Text] [Related]  

  • 27. [The anti-ischemic properties of verapamil and its effect on myocardial functional potentials in coronary artery occlusion].
    Paperno AA; Kovalev GV; Gurbanov KG
    Farmakol Toksikol; 1991; 54(2):26-8. PubMed ID: 1884790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of isoptin on intrahepatic and central hemodynamics in ischemic heart disease].
    Komissarov VA
    Klin Med (Mosk); 1987 Sep; 65(9):64-7. PubMed ID: 3695314
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evaluation of the effect of verapamil on the tolerance for exertion in coronary patients].
    Miraglia G; Stritoni P; Egloff C; Scattolin G; Contessotto F; Passarin N; Dalla Volta S
    Boll Soc Ital Cardiol; 1979; 24(5):583-9. PubMed ID: 553643
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of verapamil on pH of ischemic canine myocardium.
    Watson RM; Markle DR; McGuire DA; Vitale D; Epstein SE; Patterson RE
    J Am Coll Cardiol; 1985 Jun; 5(6):1347-54. PubMed ID: 3998317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of verapamil in long-term treatment of coronary disease, hypertension and functional disorders of the cardiovascular system].
    Tkaczewski W; Goch JH
    Wiad Lek; 1979 Oct; 32(19):1359-62. PubMed ID: 506277
    [No Abstract]   [Full Text] [Related]  

  • 32. [Isoptin in the treatment of ischemic heart disease].
    Gol'dberg VA
    Vrach Delo; 1969; 12():121. PubMed ID: 5375610
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of verapamil on myocardial contractility in ischemic cardiopathy: indirect evaluation by the polycardiographic method].
    Bielli M; Glenzer R; Beltrami M; Brunelli L; Riggio G
    Boll Soc Ital Cardiol; 1981; 26(11):1681-2. PubMed ID: 7349225
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ergometric and clinical results of treating coronary disease with isosorbide dinitrate and verapamil].
    Pozenel H
    Med Welt; 1981 Jun; 32(24):988-92. PubMed ID: 7253907
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of verapamil on the functional status of thrombocytes in patients with ischemic heart disease].
    Belousov IuB; Azizova OA; Razumov VB; Gutkin AB; Borin ML
    Kardiologiia; 1989 Feb; 29(2):42-5. PubMed ID: 2724766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coronary disease. Clinical experience with a new active substance combination].
    Bouzo H
    Med Welt; 1977 Dec; 28(49):2001-7. PubMed ID: 340839
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparative study of the medium term use of verapamil and perhexiline in the treatment of chronic coronary insufficiency. Clinical and cycloergometric evaluation].
    Candau LA; Padilha JC; Tasca R; de Patta M; Weiskopf JS; Scherr C
    Arq Bras Cardiol; 1978 Feb; 31 Suppl 1():51-62. PubMed ID: 678165
    [No Abstract]   [Full Text] [Related]  

  • 38. [Assessment of therapeutic effects of Verapamil by means of an exercise test].
    Goch JH; Rec A; Bala T
    Pol Tyg Lek; 1975 Sep; 30(36):1497-8. PubMed ID: 1161614
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of coronary disease patients with Verapamil (Isoptin)].
    Buttolo R; Nardoni A
    Minerva Cardioangiol; 1972 Jan; 20(1):7-21. PubMed ID: 4258309
    [No Abstract]   [Full Text] [Related]  

  • 40. [Initial experience. Comparative study of verapamil and nifedipine in the treatment of coronary insufficiency. Evaluation by a cycloergometric test].
    Figueira RH; Guimarães F; Wagner M; Bozza AE; Dohmann HJ
    Arq Bras Cardiol; 1978 Feb; 31 Suppl 1():39-43. PubMed ID: 354612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.